
North America Viral Vector Manufacturing Market Report and Forecast 2024-2032
Description
North America Viral Vector Manufacturing Market Report and Forecast 2024-2032
North America Viral Vector Manufacturing Market Report and Forecast 2024-2032
North America Viral Vector Manufacturing Market Outlook
The North America viral vector manufacturing market size was valued at USD 4.2 billion in 2023, driven by the increased funding for the development of gene therapies in the region. The market is expected to grow at a CAGR of 7.20% during the forecast period of 2024-2032, with the values likely to rise from USD 4.5 billion in 2024 to USD 7.9 billion by 2032.
Key Takeaways
- In November 2023 , Genezen secured USD 18.5 million funding to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to its growing clientele of cell and gene therapy innovators.
- The North America viral vector manufacturing market share is significantly impacted by the rising preference for personalised medicines to tackle chronic diseases.
- In September 2023 , Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Located at Plainville, Massachusetts, the development is projected to boost viral vector production as well as gene therapy production.
One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players supported by major financial investments. In November 2023 , Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing led by Ampersand Capital Partners which aimed to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to their cell and gene therapy innovators. Such investments are also poised to foster technological innovation and expansion of manufacturing sites and is expected to meet the growing North America viral vector manufacturing market demand.
In September 2023 , Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Situated at Plainville, Massachusetts, the company intended to make use of its 400,000 square feet viral vector manufacturing unit to boost viral vector production along with gene therapy production simultaneously. These initiatives mark as one of the most impactful North America viral vector manufacturing market trends, expected to help in accelerating the development and commercialization of life-saving therapies which will ultimately impact the market dynamics.
Other factors that influence the market share include the advancement in the healthcare infrastructure, increased research efforts aimed at finding novel therapeutics, and the improvement in regulatory reforms.
North America Viral Vector Manufacturing Market Segmentation
North America viral vector manufacturing market analysis include a detailed breakup of the market based on the following segments:
Market Breakup by Type
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Lentiviral Vectors
- Retroviral Vectors
- Others
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
- Transient
- Stable
- Gene Therapy
- Vaccinology
- Therapeutics Development
- Research
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- CDMO &CROs
- Others
- United States of America
- Canada
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Charles River Laboratories
- Finvector
- Kaneka Eurogentec SA
- Merck KGaA
- UniQure NV
- Oxford Biomedica PLC
- AstraZeneca
- Vibalogics
- Sanofi
- F.Hoffmann-La Roche Ltd
FAQs
- What was the North America viral vector manufacturing market value in 2023?
- What is the North America viral vector manufacturing market forecast outlook for 2024-2032?
- What are the major factors aiding the North America viral vector manufacturing market demand?
- What are the major North America viral vector manufacturing market trends?
- What is the market segmentation based on type?
- What are the various expression systems available in the market?
- What is the market breakup by disease?
- What are the major end users of viral vector manufacturing?
- What are the applications of viral vector manufacturing?
- What is the market segmentation by countries?
- Who are the key players involved in the North America viral vector manufacturing market?
Meta description
The North America viral vector manufacturing market size was valued at USD 4.2 billion in 2023 and it is anticipated to grow at a CAGR of 7.16% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
120 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 North America Viral Vector Manufacturing Market Overview
- 3.1 North America Viral Vector Manufacturing Market Historical Value (2017-2023)
- 3.2 North America Viral Vector Manufacturing Market Forecast Value (2024-2032)
- 4 North America Viral Vector Manufacturing Market Landscape*
- 4.1 North America Viral Vector Manufacturing: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 North America Viral Vector Manufacturing: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Disease
- 4.2.3 Analysis by Application
- 5 North America Viral Vector Manufacturing Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 North America Viral Vector Manufacturing Market Segmentation (2017-2032)
- 6.1 North America Viral Vector Manufacturing Market (2017-2032) by Type
- 6.1.1 Market Overview
- 6.1.2 Adenoviral Vectors
- 6.1.3 Adeno-associated Viral Vectors
- 6.1.4 Lentiviral Vectors
- 6.1.5 Retroviral Vectors
- 6.1.6 Others
- 6.2 North America Viral Vector Manufacturing Market (2017-2032) by Disease
- 6.2.1 Market Overview
- 6.2.2 Cancer
- 6.2.3 Genetic Disorders
- 6.2.4 Infectious Diseases
- 6.2.5 Others
- 6.3 North America Viral Vector Manufacturing Market (2017-2032) by Expression System
- 6.3.1 Market Overview
- 6.3.2 Transient
- 6.3.3 Stable
- 6.4 North America Viral Vector Manufacturing Market (2017-2032) by Application
- 6.4.1 Market Overview
- 6.4.2 Gene Therapy
- 6.4.3 Vaccinology
- 6.4.4 Therapeutics Development
- 6.4.5 Research
- 6.5 North America Viral Vector Manufacturing Market (2017-2032) by End User
- 6.5.1 Market Overview
- 6.5.2 Pharmaceutical and Biotechnology Companies
- 6.5.3 Research Institutes
- 6.5.4 CDMO & CROs
- 6.5.5 Others
- 6.6 North America Viral Vector Manufacturing Market (2017-2032) by Countries
- 6.6.1 Market Overview
- 6.6.2 United States of America
- 6.6.3 Canada
- 7 United States of America Viral Vector Manufacturing Market (2017-2032)
- 7.1 United State of America Viral Vector Manufacturing Market (2017-2032) by Type
- 7.1.1 Market Overview
- 7.1.2 Adenoviral Vectors
- 7.1.3 Adeno-associated Viral Vectors
- 7.1.4 Lentiviral Vectors
- 7.1.5 Retroviral Vectors
- 7.1.6 Others
- 7.2 United State of America Viral Vector Manufacturing Market (2017-2032) by Disease
- 7.2.1 Market Overview
- 7.2.2 Cancer
- 7.2.3 Genetic Disorders
- 7.2.4 Infectious Diseases
- 7.2.5 Others
- 7.3 United State of America Viral Vector Manufacturing Market (2017-2032) by Expression System
- 7.3.1 Market Overview
- 7.3.2 Transient
- 7.3.3 Stable
- 7.4 United State of America Viral Vector Manufacturing Market (2017-2032) by Application
- 7.4.1 Market Overview
- 7.4.2 Gene Therapy
- 7.4.3 Vaccinology
- 7.4.4 Therapeutics Development
- 7.4.5 Research
- 7.5 United State of America Viral Vector Manufacturing Market (2017-2032) by End User
- 7.5.1 Market Overview
- 7.5.2 Pharmaceutical and Biotechnology Companies
- 7.5.3 Research Institutes
- 7.5.4 CDMO &CROs
- 7.5.5 Others
- 8 Canada Viral Vector Manufacturing Market (2017-2032)
- 8.1 Canada Viral Vector Manufacturing Market (2017-2032) by Type
- 8.1.1 Market Overview
- 8.1.2 Adenoviral Vectors
- 8.1.3 Adeno-associated Viral Vectors
- 8.1.4 Lentiviral Vectors
- 8.1.5 Retroviral Vectors
- 8.1.6 Others
- 8.2 Canada Viral Vector Manufacturing Market (2017-2032) by Disease
- 8.2.1 Market Overview
- 8.2.2 Cancer
- 8.2.3 Genetic Disorders
- 8.2.4 Infectious Diseases
- 8.2.5 Others
- 8.3 Canada Viral Vector Manufacturing Market (2017-2032) by Expression System
- 8.3.1 Market Overview
- 8.3.2 Transient
- 8.3.3 Stable
- 8.4 Canada Viral Vector Manufacturing Market (2017-2032) by Application
- 8.4.1 Market Overview
- 8.4.2 Gene Therapy
- 8.4.3 Vaccinology
- 8.4.4 Therapeutics Development
- 8.4.5 Research
- 8.5 Canada Viral Vector Manufacturing Market (2017-2032) by End User
- 8.5.1 Market Overview
- 8.5.2 Pharmaceutical and Biotechnology Companies
- 8.5.3 Research Institutes
- 8.5.4 CDMO &CROs
- 8.5.5 Others
- 9 Regulatory Framework
- 10 Patent Analysis
- 10.1 Analysis by Type of Patent
- 10.2 Analysis by Publication year
- 10.3 Analysis by Issuing Authority
- 10.4 Analysis by Patent Age
- 10.5 Analysis by CPC Analysis
- 10.6 Analysis by Patent Valuation
- 10.7 Analysis by Key Players
- 11 Funding and Investment Analysis
- 11.1 Analysis by Funding Instances
- 11.2 Analysis by Type of Funding
- 11.3 Analysis by Funding Amount
- 11.4 Analysis by Leading Players
- 11.5 Analysis by Leading Investors
- 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
- 12.1 Analysis by Partnership Instances
- 12.2 Analysis by Type of Partnership
- 12.3 Analysis by Leading Players
- 12.4 Analysis by Geography
- 13 Supplier Landscape
- 13.1 Market Share by Top 5 Companies
- 13.2 Charles River Laboratories
- 13.2.1 Financial Analysis
- 13.2.2 Product Portfolio
- 13.2.3 Demographic Reach and Achievements
- 13.2.4 Mergers and Acquisitions
- 13.2.5 Certifications
- 13.3 Finvector
- 13.3.1 Financial Analysis
- 13.3.2 Product Portfolio
- 13.3.3 Demographic Reach and Achievements
- 13.3.4 Mergers and Acquisitions
- 13.3.5 Certifications
- 13.4 Kaneka Eurogentec SA
- 13.4.1 Financial Analysis
- 13.4.2 Product Portfolio
- 13.4.3 Demographic Reach and Achievements
- 13.4.4 Mergers and Acquisitions
- 13.4.5 Certifications
- 13.5 Merck KGaA
- 13.5.1 Financial Analysis
- 13.5.2 Product Portfolio
- 13.5.3 Demographic Reach and Achievements
- 13.5.4 Mergers and Acquisitions
- 13.5.5 Certifications
- 13.6 UniQure NV
- 13.6.1 Financial Analysis
- 13.6.2 Product Portfolio
- 13.6.3 Demographic Reach and Achievements
- 13.6.4 Mergers and Acquisitions
- 13.6.5 Certifications
- 13.7 Oxford Biomedica PLC
- 13.7.1 Financial Analysis
- 13.7.2 Product Portfolio
- 13.7.3 Demographic Reach and Achievements
- 13.7.4 Mergers and Acquisitions
- 13.7.5 Certifications
- 13.8 AstraZeneca
- 13.8.1 Financial Analysis
- 13.8.2 Product Portfolio
- 13.8.3 Demographic Reach and Achievements
- 13.8.4 Mergers and Acquisitions
- 13.8.5 Certifications
- 13.9 Vibalogics
- 13.9.1 Financial Analysis
- 13.9.2 Product Portfolio
- 13.9.3 Demographic Reach and Achievements
- 13.9.4 Mergers and Acquisitions
- 13.9.5 Certifications
- 13.10 Sanofi
- 13.10.1 Financial Analysis
- 13.10.2 Product Portfolio
- 13.10.3 Demographic Reach and Achievements
- 13.10.4 Mergers and Acquisitions
- 13.10.5 Certifications
- 13.11 F. Hoffmann-La Roche Ltd
- 13.11.1 Financial Analysis
- 13.11.2 Product Portfolio
- 13.11.3 Demographic Reach and Achievements
- 13.11.4 Mergers and Acquisitions
- 13.11.5 Certifications
- 14 North America Viral Vector Manufacturing Market – Distribution Model (Additional Insight)
- 14.1 Overview
- 14.2 Potential Distributors
- 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
- 16.1 Very Small Companies
- 16.2 Small Companies
- 16.3 Mid-Sized Companies
- 16.4 Large Companies
- 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
- 17.1 Government Funded
- 17.2 Private Insurance
- 17.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.